维多珠单抗治疗的炎症性肠病患者关节表现
回顾性单中心研究纳入112例接受维多珠单抗(VDZ)治疗的炎症性肠病(IBD)患者,平均随访11.4个月,32例(28.6%)出现35次肌肉骨骼表现,其中17次为炎症性;唯一的关联因素是既往炎症性关节表现史(43.8% vs 12.5%,P=0.007)。作者认为炎症性关节表现更可能与停用抗TNF而非VDZ本身相关。
要点
- VDZ治疗的IBD患者中28.6%出现肌肉骨骼表现,但仅约一半为炎症性。
- 仅3例(2.6%)可考虑为VDZ相关矛盾性脊柱关节炎。
- 既往炎症性关节表现史与炎症性关节表现发生相关(P=0.007)。
核心结论
- VDZ治疗的IBD患者中肌肉骨骼表现发生率近30%,但仅半数為炎症性,且多数炎症性表现可能与停用抗TNF相关而非VDZ本身。
研究设计与样本
- 回顾性单中心研究,纳入2013至2017年连续接受VDZ治疗的IBD患者112例,其中溃疡性结肠炎59例、克罗恩病49例、未定型结肠炎4例。
主要发现
- 平均随访11.4(8.6)个月,32例(28.6%)患者出现35次肌肉骨骼表现,其中机械性18次、炎症性17次。
- 炎症性表现中11例为轴性或外周脊柱关节炎,5例为早期可逆性关节痛,1例为软骨钙质沉着症。
- 11例脊柱关节炎中仅3例(2.6%)IBD处于非活动期,可考虑为矛盾性脊柱关节炎。
- 既往有炎症性关节表现史者炎症性关节表现发生率更高(7/16(43.8%)vs 10/80(12.5%),P=0.007)。
关键数值与推荐
- 炎症性关节表现与既往炎症性关节表现史相关:7/16(43.8%)vs 10/80(12.5%),P=0.007。
临床怎么用
- 对IBD患者启动VDZ前应询问炎症性关节表现史,治疗中出现关节症状需鉴别机械性与炎症性,并考虑既往抗TNF停用因素。
局限性
- 回顾性单中心设计,样本量有限,91.1%患者曾使用抗TNF,可能混杂停药效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Vedolizumab (VDZ) has been incriminated in the occurrence of articular manifestations in patients with inflammatory bowel diseases (IBDs). The aim of this study was to describe musculoskeletal manifestations occurring in IBD patients treated by VDZ and to identify risk factors. METHODS: In this retrospective monocentric study, we included all consecutive patients treated by VDZ for IBD in our hospital. Incident musculoskeletal manifestations occurring during VDZ treatment were analysed and characteristics of patients with and without articular inflammatory manifestations were compared. RESULTS: Between 2013 and 2017, 112 patients were treated with VDZ for IBD: ulcerative colitis (n = 59), Crohn's disease (n = 49) and undetermined colitis (n = 4). Four patients (3.6%) had a history of SpA, whereas 13 (11.6%) had a history of peripheral arthralgia. Some 102 (91.1%) patients had previously received anti-TNF. After a mean (S.d.) follow-up of 11.4 (8.6) months, 32 (28.6%) patients presented 35 musculoskeletal manifestations, of which 18 were mechanical and 17 inflammatory. Among the latter, 11 had axial or peripheral SpA, 5 had early reversible arthralgia and 1 had chondrocalcinosis (n = 1). Among the 11 SpA patients, only 3 (2.6%) had inactive IBD and may be considered as paradoxical SpA. The only factor associated with occurrence of inflammatory manifestations was history of inflammatory articular manifestation [7/16 (43.8%) vs 10/80 (12.5%), P = 0.007]. CONCLUSION: Musculoskeletal manifestations occurred in almost 30% of IBD patients treated with VDZ, but only half of them were inflammatory. Since most of the patients previously received anti-TNF, occurrence of inflammatory articular manifestations might rather be linked to anti-TNF discontinuation than to VDZ itself.
引用
- Dupré A, Collins M, Nocturne G, et al. Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab. Rheumatology (Oxford). 2020. PMID: 32259251. doi:10.1093/rheumatology/keaa107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。